Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

598
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
598
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

615
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
615
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytochrome b<sub>5</sub> reductase 3 overexpression and dietary nicotinamide riboside supplementation promote distinctive mitochondrial alterations in distal convoluted tubules of mouse kidneys during aging.

Aging cell·2024
Same author

New advances in genomics and epigenetics in antiphospholipid syndrome.

Rheumatology (Oxford, England)·2024
Same author

Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis.

European journal of internal medicine·2023
Same author

Splicing machinery is profoundly altered in systemic lupus erythematosus and antiphospholipid syndrome and directly linked to key clinical features.

Journal of autoimmunity·2023
Same author

Diagnostic value of quantitative SPECT/CT in assessing active sacroiliitis in patients with axial spondylarthritis and/or inflammatory low back pain.

Anales del sistema sanitario de Navarra·2021

Related Experiment Video

Updated: Apr 9, 2026

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.8K

Immunotherapy in antiphospholipid syndrome.

Ch Lopez-Pedrera1, M A Aguirre1, P Ruiz-Limon1

  • 1Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

International Immunopharmacology
|June 19, 2015
PubMed
Summary

Antiphospholipid syndrome (APS) involves blood clots and pregnancy issues due to antiphospholipid antibodies. Current treatments are limited, prompting research into new therapies for better outcomes.

Keywords:
Antiphospholipid syndromeNew therapeutic approachesPathogenesis

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Related Experiment Videos

Last Updated: Apr 9, 2026

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.8K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.2K

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics

Background:

  • Antiphospholipid syndrome (APS) is defined by thrombosis and/or pregnancy morbidity associated with antiphospholipid antibodies.
  • While thrombosis is a primary feature, APS encompasses a broader range of manifestations, including neurological, hematological, and cardiovascular complications.
  • Understanding the pathogenicity of antiphospholipid antibodies is crucial for developing effective treatments.

Purpose of the Study:

  • To review the current understanding of antiphospholipid syndrome (APS) and its associated manifestations.
  • To discuss the limitations of existing therapies for APS, including anticoagulation and obstetric management.
  • To explore emerging and potential novel therapeutic strategies for APS.

Main Methods:

  • Literature review of studies on antiphospholipid antibody pathogenicity.
  • Analysis of current treatment protocols for thrombotic and obstetric APS.
  • Evaluation of proposed new therapeutic approaches, including novel anticoagulants, immunomodulators, and targeted therapies.

Main Results:

  • Antiphospholipid antibodies contribute to a wide array of clinical manifestations beyond thrombosis.
  • Standard anticoagulation and current obstetric management strategies have limitations, with a significant percentage of obstetric cases remaining unsuccessful.
  • Several new therapeutic avenues are under investigation, offering potential improvements in managing APS.

Conclusions:

  • APS is a complex autoimmune disorder with diverse clinical presentations.
  • Existing treatments for APS, while foundational, are not universally effective, necessitating further research.
  • Emerging therapies targeting various pathways hold promise for improving the management and outcomes of patients with APS.